Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...

Adjuvant treatment with cemiplimab (Libtayo) significantly improves disease-free survival (DFS) in patients with high-risk cutaneous squamous cell carcinoma (CSCC) after surgery, according to new ...

Cemiplimab (Libtayo, Regeneron Pharmaceuticals) — a fully human PD-1-blocking antibody — is approved in the United States for treatment of people with cutaneous squamous cell carcinoma that ...

Regeneron Pharmaceuticals has shared positive results from a late-stage trial of Libtayo (cemiplimab) in patients with high-risk cutaneous squamous cell carcinoma (CSCC) after surgery. The phase 3 ...

Libtayo (cemiplimab). The supply agreement supports the evaluation of Immuneering’s lead product candidate, IMM-1-104, in combination with Libtayo in patients with unresectable or metastatic RAS ...